Literature DB >> 9411277

[Assessment of therapy outcome within the scope of quality assurance in a psychiatric clinic. A report of experiences].

T Wetterling1, K Junghanns, H Müssigbrodt, H J Freyberger, H Dilling.   

Abstract

A recent modification of German law requires quality assurance of inpatient treatment, i.e., of the quality of therapy, allowing comparison of different hospitals. In this paper a program developed to assess the outcome by means of international, frequently applied psychopathometric scales is presented. This program was evaluated in a study of 258 psychiatric inpatients. This study emphasized the identification of patients with long-term hospitalization and/or worse outcome. A concept to disclose these so-called 'problematic' patients by means of easily administered scales like the SCL90-R, GAF and WHO-Disability-Diagnostic-Scale (DDS) has been developed. Patients with a very long hospital stay (> 70 days) show a higher number and more severe symptoms in the self-rating (SCL90-R) at admission than the subjects with a short hospital stay. This pilot study demonstrated that a routine outcome analysis can be used for quality management in psychiatry.

Entities:  

Mesh:

Year:  1997        PMID: 9411277     DOI: 10.1007/s001150050189

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  2 in total

1.  Drug usage as a treat to the stability of treatment outcome: a one-year follow-up study of adolescent psychiatric patients.

Authors:  Albert Eduard Boon; Sjoukje Berdina Beike de Boer
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-09-08       Impact factor: 4.785

2.  [Evaluation of therapy outcome on a psychiatric admission ward. Background, methods and first results of a project on quality management].

Authors:  Anja Wilkening; Michael Zeschky; Marc Ziegenbein; Hans Pfefferer-Wolf; Elke Harms; Gudrun Lübbe; Renate Bläsing; Matthias Albert; Wielant Machleidt; Iris Tatjana Calliess
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.